A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease
Overview
- Phase
- Phase 2
- Intervention
- Rituximab
- Conditions
- Interstitial Lung Disease
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Enrollment
- 104
- Locations
- 1
- Primary Endpoint
- Absolute change in FVC
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many other connective tissue diseases (CTDs) such as polymyositis/dermatomyositis and mixed connective tissue disease. When ILD is extensive and/or progressive, immunosuppressive medication is often required to stabilize lung disease and alleviate symptoms. Current standard care for CTD associated ILD is extrapolated from studies performed in individuals with systemic sclerosis and comprises low dose corticosteroids and intravenous cyclophosphamide followed by oral azathioprine. In some individuals even this intensive immunosuppression is insufficient to prevent deterioration, and in a significant minority of affected individuals this results in respiratory failure and death. Rituximab has recently been reported as an effective 'rescue therapy' for stabilizing and even improving ILD in this patient group. Based on observations gained from this experience, the investigators believe that rituximab is a potential important alternative to current best therapy for this patient group. This study has therefore been initiated to evaluate the efficacy of rituximab (compared with standard therapy) in patients with progressive CTD related ILD.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 to 80 years at visit 1
- •A diagnosis of connective tissue disease, based on internationally accepted criteria, in one of the following categories21-24: (see Appendix 1 for details)
- •Systemic sclerosis
- •Idiopathic interstitial myopathy (including polymyositis/dermatomyositis)
- •Mixed connective tissue disease
- •Severe and/or progressive interstitial lung disease associated with the underlying connective tissue disease.
- •Chest HRCT performed within 12 months of study visit 1
- •Intention of the caring physician to treat the ILD with intravenous cyclophosphamide (with treatment indications including deteriorating symptoms attributable to ILD, deteriorating lung function tests, worsening gas exchange or extent of ILD at first presentation) and where there is a reasonable expectation that immunosuppressive treatment with stabilize or improve CTD-ILD. In individuals with scleroderma it is anticipated that subjects will fulfil the criteria for extensive disease defined by Goh et al19
- •Able to provide written informed consent
Exclusion Criteria
- •Age \<18 or \>80 years.
- •Previous treatment with rituximab and/or intravenous cyclophosphamide
- •Known hypersensitivity to rituximab or cyclophosphamide or their components
- •Significant (in the opinion of the investigator) other organ co-morbidity including cardiac, hepatic or renal impairment
- •Co-existent obstructive pulmonary disease (e.g. asthma, COPD, emphysema) with pre bronchodilator FEV1/FVC \< 70%
- •Patients at significant risk for infectious complications following immunosuppression, including; HIV positive or other immunodeficiency syndromes (including hypogammaglobulineamia)
- •Suspected or proven untreated tuberculosis
- •Viral hepatitis
- •Infection requiring antibiotic treatment in the preceding four weeks
- •Unexplained neurological symptoms (which may be suggestive of progressive mutifocal leukoencephalopathy; PML). Neurological symptoms arising as a consequence of the underlying CTD do not necessitate exclusion.
Arms & Interventions
Rituximab
1g given at baseline and two weeks.
Intervention: Rituximab
Cyclophosphamide
Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
Intervention: Cyclophosphamide
Outcomes
Primary Outcomes
Absolute change in FVC
Time Frame: 48 weeks
Secondary Outcomes
- • Change from baseline in diffusing capacity for carbon monoxide (DLco)(48 weeks)
- • Change from baseline in health related quality of life scores(48 weeks)
- • Change from baseline in global disease activity score(48 weeks)
- • Progression free survival(48 weeks)
- • Adverse and serious adverse events (as defined in GCP)(48 weeks)